Article

Reflections on the Impact of COVID-19: A Short Expert Series

Author(s):

This specialty series is dedicated to assessing the impact COVID-19 has had on the quality of life of patients with neurological disorders and the clinicians who were forced to adapt during this unique era of medical history.

COVID-19’s Impact on Telemedicine: Benefits and Limitations

COVID-19’s Impact on Clinical Care Strategies: Adopting New Methods

COVID-19’s Impact on Neurological Disorder Pathology

COVID-19’s Impact on Treatment Regimens: Did Recommendations Change?

Resources, Tools Constructed to Adapt to COVID-19 Pandemic

COVID-19’s Impact on Health Care Workers and Mental Health

Reflections on COVID-19: What We Know About the Neurologic Symptoms

As 2020 comes to a close, the year’s reputation has been marred by the impact of COVID-19, which has surpassed 75 million global cases, including more than 17 million in the United States alone. There have been more than 300,000 reported deaths of Americans from the virus, leaving hundreds of thousands of families without loved ones, and many more still nervous and in fear of exposure.

Throughout this time, there have been governmental lockdowns, statewide restrictions, and shutdowns of some of the activities that civilians cherish the most. The standard of clinical care has evolved and changed throughout the year as well, with both clinicians and patients alike forced to make adjustments.

To review how the global pandemic affected neurology and the communities within it, we’ve developed “Reflections on the Impact of COVID-19: A Short Expert Series.” Over the next week, each day we will be launching pieces dedicated to some of the major topics surrounding the pandemic, with links to some of our most notable interviews and conversations with clinicians from throughout the year.

We dive into telemedicine and technology, the changing and adopting of new treatment strategies, how COVID-19 impacts neurological disorder pathology, the thesis behind changing treatment regimens, resources and tools constructed to adapt to the pandemic, neurologic symptoms of this novel disease, and the protection of health care workers and their mental health.

Though the FDA has begun approving COVID-19 vaccines, there was still an average of more than 200,000 cases per day in US for the week leading up to Christmas, according to The New York Times tracking project.

Be sure to check back here throughout December to read the latest segments of our series. You can also use the banner image above to navigate back to this page, which we’ll continue to update with links to our newest pieces of content as we near 2021.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
 Xavier Montalban, MD, PhD
Marcello Moccia, MD, PhD
Mikael Cohen, MD
Robert J. Fox, MD; Andreas Muehler, MD, MBA
© 2024 MJH Life Sciences

All rights reserved.